INTRODUCTION
============

Subclinical hypothyroidism (SHT) is a disorder characterized by elevated serum thyroid-stimulating hormone (TSH) levels despite normal free thyroid hormone values.[@b1-cln_66p1321] The prevalence of SHT ranges from 5 to 10%, and the condition affects 6 to 10% of women (approximately 15% of women over 60 years of age) and 2.4 to 3% of the male population.[@b2-cln_66p1321],[@b3-cln_66p1321] A recent meta-analysis demonstrated that SHT can lead to an increased risk of developing cardiovascular disease and, consequently, elevate cardiovascular-associated mortality, especially in patients under 65 years of age.[@b4-cln_66p1321]-[@b6-cln_66p1321] However, different authors propose that this higher risk does not apply to all patients with SHT, especially when the serum TSH is only slightly elevated and there are no other associated cardiovascular risks.[@b7-cln_66p1321] It is unclear whether the association between SHT and coronary artery disease is related to SHT-induced changes in serum lipid levels.[@b8-cln_66p1321]-[@b10-cln_66p1321] In a population-based survey, SHT emerged as a significant risk factor for aortic atherosclerosis and myocardial infarction in elderly women independently of serum cholesterol level.[@b11-cln_66p1321] Therefore, further studies should clarify the role of SHT in cardiovascular disease.

The endothelium plays a major role in the maintenance of vascular function and integrity through the production of vasodilator and vasoconstrictor substances.[@b12-cln_66p1321],[@b13-cln_66p1321] Endothelial dysfunction that results in reduced availability of nitric oxide is an early marker of atherosclerosis and can be used to predict coronary artery disease before the development of atherosclerotic changes.[@b14-cln_66p1321] Recent studies have shown that hypothyroidism and SHT may have adverse effects on endothelial function independently of other well-known atherosclerotic risk factors.[@b15-cln_66p1321]-[@b22-cln_66p1321] Considerable controversy surrounds the hypothesis that SHT has a significant effect on the risk profile of cardiovascular disease. Boekholdt et al.[@b23-cln_66p1321] provided important information that addressed this issue. Although higher elevated LDL cholesterol levels were found in the SHT group, thyroid dysfunction was not linked with a significantly increased risk of coronary heart disease. Despite the association between thyroid hormone levels and cardiovascular risk factors, thyroid status was not statistically significantly associated with the risk of future coronary heart disease or all-cause mortality in that large cohort over a follow-up of 10.6 years. The endothelial physiology in SHT and the role of levothyroxine (L-T4) therapy in improving endothelial function are still uncertain.

We previously reported no differences in flow-mediated vasodilatation (FMD) of the brachial artery and carotid artery intima-media thickness (IMT) in a group of women with mild SHT without previously diagnosed cardiovascular disease compared with euthyroid subjects.[@b24-cln_66p1321],[@b25-cln_66p1321]

The aims of the present study were to assess the effect of L-T4 replacement on endothelial function measured by FMD of the brachial artery, as well as carotid artery IMT in a group of female patients with mild SHT.

PATIENTS AND METHODS
====================

The study was a randomized open-label prospective trial comparing the use of L-T4 in female patients with mild SHT. Thirty-two women with mild SHT were recruited from the Outpatient Clinic of the Clementino Fraga Filho University Hospital (HUCFF), Federal University of Rio de Janeiro (UFRJ). The inclusion criteria were at least two documented laboratory determinations of SHT conducted at least six weeks apart, as defined by both elevated TSH (\>4.0 µIU/ml) and normal free thyroxine (FT4) levels. The patients had no previous history of thyroid disease. The maximum TSH value accepted was 12 µIU/ml. This cutoff represents three times the superior acceptable limit of the TSH level, which is 4 µIU/ml. Individuals were excluded from the study if they had a history of alcohol use or were suffering from any cardiovascular disease or concomitant non-thyroid illnesses (e.g., obesity, diabetes mellitus, arterial hypertension, liver, or renal diseases). We examined their personal histories, physical examinations, and laboratory tests. The routine laboratory test included kidney function tests (urea, creatinine), liver function tests (ALT, AST, and GGT), and mean glycemia.

The routine laboratory chemistry was normal in all patients, and no patient was taking any drug that could interfere with thyroid, lipoprotein, or endothelial function. The drugs that could interfere included amiodarone, corticosteroids, estrogens, lithium, statins, diuretics, and fibrates; additional drugs were used to treat diabetes, arterial hypertension, or obesity. The patients had no history of recent hospitalization. Patients with SHT were randomly allocated to treatment with L-T4 (levothyroxine group) or no treatment (observation group). Fixed-block numbers were used to generate the random allocation sequence of the treatment group. Each patient received a number in a block of four or six random numbers. Each number corresponded to one of the follow-up groups (levothyroxine group or observation group). Blocks of six and four numbers were continuously distributed, and each block had half of the numbers corresponding to treatment and another half corresponding to observation. For those patients who were treated, the initial L-T4 dose was 0.75 µg/kg/day. Patients were re-evaluated every four weeks based on the clinical evaluation (including diet habits and physical activity) and TSH and FT4 levels to adjust the dose. The dose that achieved a normal serum TSH was subsequently maintained. After a normal TSH level was obtained, patients were seen every three months to assess the presence of adverse effects, disease progression, and whether the L-T4 dose needed adjustment. The patients in the observation group (OG) were re-evaluated every four weeks, and blood tests were used to measure TSH and FT4 levels.

All patients were instructed to reduce the fat in their daily diet. The patients received general recommendations of a healthy diet, including the following: consume fish, especially oily fish, at least twice a week; limit the intake of saturated fat and trans fat by choosing lean meats and vegetable alternatives, as well as fat-free or low-fat dairy products and minimizing the intake of partially hydrogenated fats; minimize the intake of beverages and foods with added sugars; and choose and prepare foods with little or no salt. These recommendations were written and provided to all patients.

A re-evaluation of serum lipids, FMD and carotid IMT was performed one year after the restoration of the euthyroidism state or one year after inclusion in the group of patients with SHT who did not receive L-T4 treatment. The subjects did not use any lipid-lowering medications during the study.

The study was approved by the UFRJ Institutional Ethics Committee, and all subjects provided written informed consent to participate. The number of the protocol for the Ethics Committee in Research was 12-01.

A general physical examination was performed, including assessment of height (without shoes), weight, and waist circumference (the minimum value between the iliac crest and the lateral costal margin). BMI was calculated as the weight (kg) divided by the height squared (m^2^). Systolic and diastolic blood pressures were measured from the right brachial artery of the subjects in a supine position after 10 min of rest using a pneumatic sphygmomanometer.

Venous blood samples were drawn between 8:00 and 9:00 am after a 12-hour overnight fast. Serum was centrifuged and stored at -80°C until assayed. Serum TSH, FT4 and thyroid peroxidase antibody (TPO-Ab), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), triglyceride (TG), apoprotein B (apoB), apoprotein A (apoA), and lipoprotein a \[Lp(a)\] levels were determined in both groups.

Serum TSH, FT4 and TPO-Ab were measured by immunochemiluminescence (Immulite 2000; DPC, Diagnostic Products Corporation, USA). Reference ranges for TSH and FT4 were 0.4-4.0 µIU/ml and 0.8-1.9 ng/dl, respectively. TPO-Ab levels of \>35 IU/ml were considered positive. The intra-assay coefficients of variation were 3.8-12.5, 4.4-7.5, and 4.3-5.6% for TSH, FT4, and TPO-Ab, respectively. The inter-assay coefficients of variation were 4.6-12.5, 4.8-9.0, and 7.8-10.5%, respectively. TC and TG (Vitros Chemistry Products, USA), as well as HDL-c (Boehringer Mannheim Systems, Germany), were determined enzymatically. Low-density lipoprotein cholesterol (LDL-c) was calculated by the Friedewald equation: LDL-c  =  (TC -- HDL-c) - (TG/5). The reference ranges for TC, HDL-c, TG, and LDL-c were based on the Adult Treatment Panel III of the National Cholesterol Education Program (NCEP).[@b26-cln_66p1321] The Lp(a) concentration was determined by an immunoradiometric assay (Diagnosis System International, Novatech, USA) and apoA and apoB were measured by a rate nephelometric immunoassay (Beckman Coulter, USA), and their reference ranges were lower than 30, 90-200, and 30-100 mg/dl, respectively.

The subjects were investigated by high-resolution color-Doppler ultrasound imaging (Toshiba Nemium, Japan; 14-mHz linear probe) of the brachial artery in the dominant arm. The study was performed in a temperature-controlled room (25°C) with subjects resting in the supine position. The blood pressure and heart rate were recorded on the opposite arm every three min using an automatic sphygmomanometer. The subjects\' dominant arm was comfortably immobilized in the extended position to allow consistent access to the brachial artery. Doppler ultrasound measurements were performed before and 60 seconds after reactive hyperemia (RH). To avoid interobserver variability, all measurements were performed by the same examiner, who was blinded to the subjects\' clinical status. Brachial artery vasodilation in response to RH was determined by a previously validated technique.[@b27-cln_66p1321],[@b28-cln_66p1321] The intraclass correlation coefficient of this technique has been reported previously by our laboratory and ranges from R = 0.7001 to R = 0.8420 (*p*\<0.05).[@b29-cln_66p1321],[@b30-cln_66p1321] The scans were recorded on S-VHS videotape. The internal diameter of the brachial artery was assessed at the end of diastole, and the arterial flow was measured using the pulse Doppler sample volume at an angle of 60° or less in the center of the artery. For each subject, optimal brachial artery images were obtained approximately 5 cm above the antecubital fossa. Arm pressure was generating by inflating a pneumatic arm band above the elbow cuff to a pressure up to 30 mmHg higher than the subject\'s systolic arterial pressure for 5 min. The cuff was then deflated, the arterial flow was immediately recorded and the diameter was measured 60 to 90 seconds after deflation. For both diameters, one measurement was recorded. FMD was calculated according to the following formula: FMD  =  (post-occlusion diameter - baseline diameter) ×100/baseline diameter.

The carotid images were obtained with the patient in the supine position with the neck mildly extended and the head rotated contralaterally to the side. The imaging protocol involved obtaining a minimum of four longitudinal B-mode images of the distal 10 mm of the right and left common arteries and the carotid bifurcation. The whole image session was recorded on videotape. The IMT of the common carotid artery (CCA) and carotid bifurcation were calculated by the same examiner with high-resolution ultrasound imaging (Acuson Aspen Advanced, 10 mHz linear probe, USA), as previously described.[@b31-cln_66p1321] The final analysis was performed with IMT images of both the near and far wall of the right and left common artery and the carotid bifurcation. The recordings were evaluated by the same reader, who was blinded to the clinical data. The diastolic frames of each carotid segment were digitized. Lines were drawn along the lumen-intimal and medial adventitial interfaces in all analyzed segments, and the IMT of each segment was automatically computed as an average of several measurements. For statistical analysis, IMT readings in all the carotid segments were averaged (mean IMT). Plaque was considered as a focal structure if it encroached into the arterial lumen by at least 0.5 mm or 50% of the surrounding IMT value or demonstrated a thickness \>2.0 mm, as measured from the media-adventitia interface to the intima-lumen interface. The reproducibility of the IMT measurement was acceptable, as demonstrated by coefficients of variation of 7.7±4.3%.[@b31-cln_66p1321]

Statistical analysis
--------------------

A statistical analysis was performed using SPSS for Windows, version 10.0. The mean values of the numerical variables were compared between groups by the Mann-Whitney test if they were not normally distributed, as detected by the Kolmogorov-Smirnov Liliefors test. Parametric variables were compared by the Student t-test. Data were expressed as means ± SD values unless otherwise stated. We also determined the frequencies of qualitative variables. For multi-group comparisons, one-way analysis of variance (ANOVA) or the Kruskal-Wallis test was applied, as appropriate. Analysis of frequencies was performed with the use of contingency tables (chi-square test). Correlations between parameters were tested by Pearson or Spearman correlation coefficients. The variation in the studied variables for each SHT patient who completed the follow-up protocol was calculated. The effect of LT-4 was assessed by comparing the mean variations between the two SHT groups (treated and observational), based on a per-protocol approach. The different effects of L-T4 replacement were also assessed by comparing the means before and after intervention by the Wilcoxon Signed Rank Test or Student\'s t-test. A p value of \<0.05 was considered to be significant.

RESULTS
=======

Thirty-two female patients with mild SHT without previously treated thyroid or vascular disease were randomly assigned to 12 months of L-T4 replacement or no treatment and were evaluated. 14 patients were randomly assigned to the L-T4 treatment group (LtG), and 18 patients were randomly assigned to the observational group (OG). During the study, no patient was excluded. Both groups were similar with respect to age, BMI, waist circumference, activity level, smoking behavior, menopausal status, and laboratory and vascular parameters.

Baseline data:

[Table 1](#t1-cln_66p1321){ref-type="table"} shows the baseline information of the patients in the different studied groups. All patients had spontaneous and primary hypothyroidism, and the majority had positive circulating TPOAb ([Table 1](#t1-cln_66p1321){ref-type="table"}). No relationship between carotid IMT or brachial FMD and free T4 and TSH was found.

Follow-up data:

TSH and FT4 levels at the end of the study (12 months) are shown in [Table 2](#t2-cln_66p1321){ref-type="table"}. No significant changes were observed in BMI and waist circumference (data not shown) or in other laboratory variables ([Table 2](#t2-cln_66p1321){ref-type="table"}). The median dose of L-T4 was 44.23±18.13 µg/day.

As shown in Figure 1, there was a significant decrease in the brachial artery FMD after 12 months in the OG (*p* = 0.03) and no significant difference in FMD in the LtG (*p* = 0.39). We did not find any correlation between the carotid IMT and the studied variables or a reduction of carotid IMT after one year of LT4 treatment ([Table 2](#t2-cln_66p1321){ref-type="table"}). We found plaques in 2 patients in each group, and there was no difference after one year of treatment.

When comparing the mean changes during the study in the two TPO-Ab patients within the prospective SHT groups, no significant differences in brachial artery FMD were found (LtG, 1.13±9.5; OG -5.58±9.59; *p* = 0.12).

When the patients in each group were subdivided into low (≥4 but \<8 µIU/ml) or high (≥8 but \<12 µIU/ml) TSH levels, no differences were observed in metabolic or vascular parameters (data not shown).

A stratified analysis that considered the presence of any type of dyslipidemia based on NCEP criteria was performed. Dyslipidemia was defined as elevated TC, elevated triglycerides, elevated LDL-c and/or decreased HDL-c. There was a non-significant decrease in FMD in the OG in both subgroups (dyslipidemia present or absent) and a non-significant increase in FMD in the LtG in both subgroups. Changes in brachial FMD and carotid artery IMT after one year of follow-up in the LtG and OG based on the presence or absence of dyslipidemia are shown in [Table 3](#t3-cln_66p1321){ref-type="table"}.

DISCUSSION
==========

LT-4 treatment did not significantly improve endothelial function or reduce the carotid IMT in subjects with mild SHT who were similar with respect to age, BMI, smoking, menopausal status, and endothelial function modifiers. After one year, there was a significant decrease in brachial artery FMD in the OG and no difference in LtG, which suggests that thyroid hormone replacement could prevent a decline in FMD in patients with SHT. The exclusion of participants with concomitant hormonal, renal, or liver diseases allowed us to control our analysis for confounding variables and yielded a homogeneous population. In addition, by excluding co-morbid conditions, the mean age was reduced, allowing a smaller sample size for the study.

Few studies have evaluated carotid IMT and the effect of L-T4 replacement in subclinical thyroid dysfunction. Monzani et al.[@b15-cln_66p1321] were the first to show higher mean IMT values in SHT patients compared with age- and sex-matched controls. The maximal thickness in any particular segment was also measured (maximal IMT) and was higher in the SHT group. We previously reported no significant differences in the mean carotid IMT in a group of subclinical hypothyroid patients compared with a euthyroid group, which suggests that mild SHT is not associated with an increase in cardiovascular risk when assessed by carotid IMT.[@b24-cln_66p1321],[@b25-cln_66p1321] Monzani et al.[@b25-cln_66p1321] were also the first to evaluate the benefit of six months of L-T4 replacement therapy on IMT in patients with SHT. L-T4 significantly reduced both LDL-c and the mean IMT, suggesting that lipid infiltration of the arterial wall may represent the main mechanism underlying the increase in IMT in patients with SHT. In the present work, we did not find any association between carotid IMT and the variables studied. Furthermore, no reduction of carotid IMT was appreciated after one year of L-T4 therapy.

The cardiovascular system is a specific target of thyroid hormones (THs); thus, thyroid dysfunction is accompanied by profound changes in cardiovascular hemodynamics.[@b26-cln_66p1321],[@b27-cln_66p1321] Both the vasculature and the endothelium play pivotal roles in modulating vascular tone, and both are potential targets of THs.[@b28-cln_66p1321] Several studies have demonstrated the presence of thyroid receptors in endothelial cells.[@b32-cln_66p1321],[@b33-cln_66p1321] Some studies have suggested a role for vascular smooth muscle (VSM) cells in mediating the vasodilating effect of T3 infusion in the endothelium in human euthyroid subjects.[@b34-cln_66p1321],[@b35-cln_66p1321]

Little is known about the interaction of TSH with endothelial cells. The TSH receptor is present in the thyroid gland and, also, in many other sites, such as VSM cells.[@b34-cln_66p1321] Dardano et al. demonstrated that an acute systemic increase of serum TSH levels by rhTSH injection induced a significant impairment of endothelial vasodilatation in conduit arteries.

Few studies have evaluated the relationship between SHT and endothelial dysfunction and the effect of L-T4 replacement in the endothelial function of subclinical hypothyroid patients. Lekakis et al.[@b17-cln_66p1321] were the first to describe the negative association between borderline and mild hypothyroidism and FMD. In their study, cholesterol did not differ significantly among groups but tended to be higher in the hypothyroidism and SHT groups, and the authors concluded that higher cholesterol levels may be associated with endothelial dysfunction. Dagre et al.[@b36-cln_66p1321] noninvasively assessed the NO-dependent endothelial function of resistance arteries in subjects with hypothyroidism of varying severity by measuring the forearm blood flow response during reactive hyperemia via utilizing venous occlusion strain-gauge plethysmography. Endothelial dysfunction was only detected in the microvasculature of patients with overt hypothyroidism. We previously reported no significant differences in brachial FMD in a group of subclinical hypothyroid patients compared with a euthyroid group, which suggests that mild thyroid dysfunction had no adverse effects on endothelial function in the population studied.[@b24-cln_66p1321] Taddei et al.[@b22-cln_66p1321] showed in a group of subclinical hypothyroid patients that 6 months of euthyroidism by L-T4 replacement increased acetylcholine-induced vasodilation. They also observed a significant correlation between the maximal response to acetylcholine and changes in LDL-c. In a randomized, double-blind, crossover study of L-T4 or placebo for 12 weeks, brachial FMD was significantly improved in the group of patients who took a daily dose of 100 µg of L-T4 compared with the placebo group. Multivariate analysis showed that increased serum FT4 levels were the most significant variable predicting a reduction in TC or improvement in FMD.[@b23-cln_66p1321] Xiang et al. showed that TSH, FT3 (free T3), LDL-c and Lp(a) levels were significant factors associated with endothelium-dependent arterial dilation in Hashimoto\'s thyroiditis patients with euthyroidism.[@b35-cln_66p1321] The lack of FT3 measurement is a limitation of our study and is also important for ruling out the possible inclusion of subjects with non-thyroidal illness syndrome.

The interpretation of the results strongly depends on the effectiveness of substitutive treatment. According to the literature,[@b7-cln_66p1321] in this case, the optimal values for TSH in L-T4 treated patients are unclear. As shown in some studies, it is not uncommon for patients in clinical trials to be outside of the therapeutic target at the end of the study. Ravzi et al.[@b6-cln_66p1321] demonstrated a significant improvement in cardiovascular risk factors in a group of patients with SHT treated by LT-4, and 27 patients had discordant thyroid function tests during the course of the study.

This study was a randomized open-labeled prospective trial. A double-blind, placebo-controlled study would be a more suitable approach. Another limitation of this study was the small sample size, which makes it difficult to obtain a clear decision about the benefit of L-T4 treatment in SHT patients. More studies with larger patient populations are needed to elucidate this subject more fully.

We did not measure the maximal IMT during the internal carotid artery measurements, which could be considered a limitation of the study. An important issue is which IMT measure (e.g., mean IMT value; maximal IMT value; internal carotid artery from the anterior, lateral, and posterior angle; and composite measures from the left and right side or from different arterial sides) should be used. There is no definite answer to this question, but, for study purposes, all segments should be analyzed.

The brachial artery vasodilation in response to RH was determined by FMD of the brachial artery. FMD is an indirect way of measuring the endothelial function using vascular reactivity. We did not assess endothelium-independent vasodilatation, which could be assessed with a dose-response curve to sodium nitroprusside. While it is important to perform nitrate dilatation to confirm that the findings were not due to media disease, as opposed to endothelial dysfunction, we were unable to perform this evaluation and suggest that it be performed in future works. Some studies that assessed the response to sodium nitroprusside (which specifically acts on smooth muscle cells) have shown similar responses in both groups (control and SHT groups) and a reduced vasodilatory effect of acetylcholine in SHT patients; these results indicate that SHT is characterized by the presence of endothelial dysfunction.[@b17-cln_66p1321],[@b22-cln_66p1321]

Another limitation of this study is that we did not measure estradiol levels or the duration of menopause. This finding is important because abnormal FMD values can be obtained in older women and women who experienced a long menopausal period. Although both groups were similar in relation to age, the control group was more than four years older than the treated one; thus, the changes in FMD could be related to the development of climacterium.

In the present study, the reported mean values for TSH after treatment were in the upper limit of the normal range. Some patients were under-treated, and this finding could explain why we did not find a significant benefit after LT-4 treatment.

CONCLUSION
==========

Our data suggest that thyroid hormone replacement therapy could prevent a decline in FMD with the continuation of the SHT state in comparison with untreated subjects. Large, prospective, multicenter placebo-controlled trials are necessary to further investigate the endothelial physiology of patients with SHT and to define the role of L-T4 therapy in improving endothelial function in patients with SHT.

![Changes in FMD% in the levothyroxine-treated and observation groups.](cln-66-08-1321-g001){#f1-cln_66p1321}

###### 

Baseline data of levothyroxine-treated and observation groups.

                                 *OG*           LtG
  ------------------------------ -------------- ---------------
  Age (yr)                       47.59±8.4      43.36±9.8
  BMI (kg/m^2^)                  26.24±2.71     25.89±2.29
  Waist (cm)                     84.06±8        83.17±6.5
  Sedentary behavior (%)         94.4           85.7
  Smokers (%)                    11.1           14.3
  Menopause (%)                  55.6           50
  HRT (%)                        0              0
  Familial dyslipidemia (%)      33.3           34.4
  TSH (µUI/ml)                   6.77±1.96      6.79±2.0
  FT4 (ng/dl)                    0.95±0.15      0.97±0.13
  TPO-Ab (%)                     61.1           64.3
  TC (mg/dl)                     226.11±43.55   213.43±53.17
  HDL-c (mg/dl)                  51.83±10.28    56.78±11.15
  LDL-c (mg/dl)                  147.5±37.58    137.92±47.94
  TG (mg/dl)                     132.5±50.82    136.07±119.18
  Lipoprotein(a) (mg/dl)         53.83±62.87    61.78±62.71
  ApoB (mg/dl)                   128.61±34.16   109.28±44.15
  ApoA (mg/dl)                   148.83±24.73   150.21±24.73
  Mean IMT (mm)                  0.65±0.23      0.66±0.11
  Flow-mediated dilatation (%)   17.33±7.88     16.81±7.0

Notes: Values are expressed as means ± SD or frequency. The p values were \>0.05.

OG, observation group; LtG, levothyroxine group; HRT, hormone replacement treatment; TSH, thyroid-stimulating hormone; FT4, free thyroxine; TPO-Ab, antiperoxidase antibody; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; apoA, apoprotein A; apo B, apoprotein B; IMT, intima-media thickness; FMD, flow-mediated vasodilatation.

###### 

Initial (baseline) and final (after one year) results of the levothyroxine-treated and observation groups.

                            Observation                                                                                         group                                                                                               Levothyroxine                                                                                                 Group
  ------------------------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  TSH (mUI/ml)              6.77±1.96[b](#tfn5-cln_66p1321){ref-type="table-fn"}(4.2-11.0)                                      6.69±3,51[b](#tfn5-cln_66p1321){ref-type="table-fn"},(3.27-13.5)                                    6.79±2.0[a](#tfn4-cln_66p1321){ref-type="table-fn"},[b](#tfn5-cln_66p1321){ref-type="table-fn"}(4.04-10.65)   3.02±0.89[a](#tfn4-cln_66p1321){ref-type="table-fn"},[b](#tfn5-cln_66p1321){ref-type="table-fn"}(1.54-4.0)
  FT4 (ng/dl)               0.95±0.15                                                                                           1.06±0.15                                                                                           0.97±0.13                                                                                                     1.16±0.18
  TC (mg/dl)                226.11±43.55                                                                                        227.6±36.9                                                                                          213.43±53.1                                                                                                   208.4±36.7
  HDL-c (mg/dl)             51.83±10.28                                                                                         49.61±9.74                                                                                          56.78±11.15                                                                                                   54.36±12.3
  LDL-c (mg/dl)             147.5±37.58                                                                                         150.6±34.74                                                                                         137.92±47.94                                                                                                  132.8±37.5
  TG (mg/dl)                132.5±50.82                                                                                         137.0±56.06                                                                                         136.07±119.18                                                                                                 106.0±36.7
  Lipoprotein (a) (mg/dl)   53.83±62.87                                                                                         48.21±47.22                                                                                         61.78±62.71                                                                                                   58.87±64.09
  ApoB (mg/dl)              128.61±34.16                                                                                        125.94±27.47                                                                                        109.28±44.15                                                                                                  105.1±27.17
  ApoA (mg/dl)              148.83±24.73                                                                                        136.78±24.04                                                                                        150.21±24.73                                                                                                  144.14±25.57
  Mean IMT (mm)             0.65±0.23                                                                                           0,67±0,18                                                                                           0.66±0.11                                                                                                     0.66±0.15
  FMD (%)                   17.33±7.88[a](#tfn4-cln_66p1321){ref-type="table-fn"},[b](#tfn5-cln_66p1321){ref-type="table-fn"}   13.10±4.75[a](#tfn4-cln_66p1321){ref-type="table-fn"},[b](#tfn5-cln_66p1321){ref-type="table-fn"}   16.81±7.0 [b](#tfn5-cln_66p1321){ref-type="table-fn"}                                                         18.52±7.44 [b](#tfn5-cln_66p1321){ref-type="table-fn"}

Values are expressed as means ± SD; TSH values are expressed as the mean ± SD (interquartile range).

*p*\<0.05 comparing before and after values within each group.

*p*\<0.05 comparing the mean changes between the two prospective SHT groups during the study.

For all other values, *p*\>0.05.

TSH, thyroid-stimulating hormone; FT4, free thyroxine; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; apoA, apoprotein A; apoB, apoprotein B; IMT, intima-media thickness; FMD, flow-mediated vasodilatation.

###### 

Changes in brachial FMD and mean EIM after one year of follow-up in the L-T4 group and the observation group based on the presence or absence of dyslipidemia.

                                 *Dyslipidemia present*   Dyslipidemia absent               
  ------------------------------ ------------------------ --------------------- ----------- -----------
  Mean IMT (mm)                  0.00±0.01                0.00±0.01             0.00±0.01   0.00±0.01
  Flow-mediated dilatation (%)   -3.84±5.97               1.15±7.95             -5.0±11.7   2.46±8.62

Values are expressed as the mean changes between the two prospective SHT groups through the study. All other *p*\>0.05.

OG, observation group; LtG, levothyroxine group; FMD, flow-mediated vasodilatation; IMT, intima-media thickness.
